Bristol-Myers Squibb Company's Profit Tops Estimates on Sales Growth
Published: Oct 23, 2013
Bristol-Myers Squibb Co. (BMY) beat analysts’ third-quarter earnings and sales estimates as demand for the company’s cancer and arthritis drugs grew. Profit excluding certain items was 46 cents a share, beating the average 44 cents of 16 analysts’ estimates compiled by Bloomberg. Sales increased 9 percent to $4.07 billion, the New York-based drugmaker said in a statement.
Help employers find you! Check out all the jobs and post your resume.